Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP080
MIFTS: 50

Hypogonadism

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hypogonadism

About this section

MalaCards integrated aliases for Hypogonadism:

Name: Hypogonadism 12 74 29 54 43 15 71

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1924
MeSH 43 D007006
NCIt 49 C9227
SNOMED-CT 67 48130008
UMLS 71 C0020619
Sources

Summaries for Hypogonadism

About this section
Disease Ontology : 12 A gonadal disease that is characterized by diminished functional activity of the gonads.

MalaCards based summary : Hypogonadism is related to hypogonadotropic hypogonadism 7 with or without anosmia and hypogonadotropic hypogonadism 23 without anosmia. An important gene associated with Hypogonadism is GNRH1 (Gonadotropin Releasing Hormone 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Liraglutide and Dihydrotachysterol have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Hypogonadism means diminished functional activity of the gonads-the testes or the ovaries-that may... more...

Sources

Related Diseases for Hypogonadism

About this section

Diseases related to Hypogonadism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 897)
# Related Disease Score Top Affiliating Genes
1 hypogonadotropic hypogonadism 7 with or without anosmia 34.5 SPRY4 PROKR2 GNRHR GNRH1 FGFR1 FGF17
2 hypogonadotropic hypogonadism 23 without anosmia 34.3 PROKR2 NSMF LHB GNRHR GNRH1 ANOS1
3 congenital hypogonadotropic hypogonadism 34.0 GNRHR FGFR1 DUSP6 CHD7 ANOS1
4 hypogonadotropism 33.1 TACR3 TAC3 PROKR2 KISS1R KISS1 GNRHR
5 hypogonadotropic hypogonadism 32.9 TACR3 TAC3 SPRY4 PROKR2 PROK2 NSMF
6 normosmic congenital hypogonadotropic hypogonadism 32.9 TACR3 TAC3 SPRY4 PROKR2 PROK2 NSMF
7 premature ovarian failure 1 32.8 NR0B1 LHCGR KISS1R KISS1 GNRH1 FSHB
8 kallmann syndrome 32.7 TACR3 TAC3 SPRY4 PROKR2 PROK2 NSMF
9 charge syndrome 32.1 TACR3 TAC3 PROKR2 PROK2 NSMF KISS1R
10 amenorrhea 31.3 LHCGR LHB GNRHR GNRH1 FSHB
11 infertility 31.3 LHCGR LHB GNRH1 FSHB
12 hypopituitarism 31.2 PROKR2 PROK2 GNRH1 FSHB
13 precocious puberty 31.0 LHCGR KISS1R KISS1 GNRH1
14 renal hypodysplasia/aplasia 1 30.7 PROKR2 PROK2 GNRH1 FGFR1 ANOS1
15 ovarian hyperstimulation syndrome 30.6 LHCGR GNRH1 FSHB
16 coloboma of macula 30.6 TACR3 PROKR2 PROK2 NSMF KISS1R GNRHR
17 pseudohermaphroditism 30.6 NR0B1 LHCGR LHB
18 cryptorchidism, unilateral or bilateral 30.5 TACR3 TAC3 SPRY4 PROKR2 PROK2 NSMF
19 anovulation 30.5 KISS1 GNRH1 FSHB
20 choanal atresia, posterior 30.3 TACR3 PROKR2 PROK2 NSMF GNRHR CHD7
21 central precocious puberty 30.2 KISS1R KISS1 GNRH1
22 sex development disorder 30.1 LHCGR KISS1 GNRH1
23 pseudovaginal perineoscrotal hypospadias 29.9 LHCGR GNRH1
24 septooptic dysplasia 29.8 PROKR2 PROK2 GNRHR GNRH1 FSHB FGFR1
25 hypogonadotropic hypogonadism 1 with or without anosmia 12.6
26 hypogonadotropic hypogonadism 21 with or without anosmia 12.6
27 hypogonadotropic hypogonadism 10 with or without anosmia 12.6
28 hypogonadotropic hypogonadism 8 with or without anosmia 12.6
29 hypogonadotropic hypogonadism 12 with or without anosmia 12.6
30 hypogonadotropic hypogonadism 20 with or without anosmia 12.6
31 hypogonadotropic hypogonadism 14 with or without anosmia 12.6
32 hypogonadotropic hypogonadism 15 with or without anosmia 12.6
33 hypogonadotropic hypogonadism 11 with or without anosmia 12.6
34 hypogonadotropic hypogonadism 13 with or without anosmia 12.6
35 hypogonadotropic hypogonadism 16 with or without anosmia 12.6
36 cardiomyopathy, dilated, with hypergonadotropic hypogonadism 12.6
37 hypogonadotropic hypogonadism 9 with or without anosmia 12.6
38 hypogonadotropic hypogonadism 4 with or without anosmia 12.6
39 hypogonadotropic hypogonadism 5 with or without anosmia 12.6
40 hypogonadotropic hypogonadism 17 with or without anosmia 12.6
41 hypogonadotropic hypogonadism 19 with or without anosmia 12.6
42 hypogonadotropic hypogonadism 22 with or without anosmia 12.6
43 hypogonadotropic hypogonadism 18 with or without anosmia 12.6
44 hypogonadotropic hypogonadism 3 with or without anosmia 12.6
45 hypogonadotropic hypogonadism 2 with or without anosmia 12.6
46 hypogonadotropic hypogonadism 6 with or without anosmia 12.6
47 leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism 12.5
48 hypogonadism, male 12.5
49 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 12.5
50 hypogonadotropic hypogonadism 24 without anosmia 12.5

Graphical network of the top 20 diseases related to Hypogonadism:



Diseases related to Hypogonadism
Sources

Symptoms & Phenotypes for Hypogonadism

About this section

GenomeRNAi Phenotypes related to Hypogonadism according to GeneCards Suite gene sharing:

26 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.74 FGFR1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.74 FGFR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.74 FGFR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.74 KISS1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.74 KISS1R
6 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.74 KISS1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.74 FGFR1 KISS1 KISS1R LHB
8 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.74 KISS1R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.74 FGFR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.74 LHB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.74 KISS1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.74 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.74 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.74 FGFR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.74 LHB
16 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.74 FGFR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.74 KISS1R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.74 KISS1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.74 KISS1R
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.74 FGFR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.74 KISS1R
22 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.74 FGFR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.74 LHB

MGI Mouse Phenotypes related to Hypogonadism:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.17 CHD7 FGFR1 FSHB GNRH1 GNRHR KISS1
2 growth/size/body region MP:0005378 10.03 CHD7 DUSP6 FGFR1 GNRH1 GNRHR KISS1
3 homeostasis/metabolism MP:0005376 10.03 CHD7 DUSP6 FGFR1 FSHB GNRH1 GNRHR
4 digestive/alimentary MP:0005381 10.02 CHD7 FGFR1 GNRH1 GNRHR KISS1 KISS1R
5 nervous system MP:0003631 9.7 CHD7 FGF17 FGFR1 GNRH1 KISS1 KISS1R
6 reproductive system MP:0005389 9.5 CHD7 DCAF17 FGFR1 FSHB GNRH1 GNRHR
Sources

Drugs & Therapeutics for Hypogonadism

About this section

Drugs for Hypogonadism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2 44147092
2
Dihydrotachysterol Approved Phase 4 67-96-9 5281010 5311071
3
Metformin Approved Phase 4 657-24-9 14219 4091
4
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
5 Nutmeg Approved Phase 4
6
Menotropins Approved Phase 4 9002-68-0, 61489-71-2 5360545
7
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
8
Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
9 Hypoglycemic Agents Phase 4
10 Incretins Phase 4
11 Luteolytic Agents Phase 4
12 Triptorelin Pamoate Phase 4
13 Fenugreek seed meal Phase 4
14 Fenugreek Phase 4
15 Tranquilizing Agents Phase 4
16 Dopamine D2 Receptor Antagonists Phase 4
17 Psychotropic Drugs Phase 4
18 Serotonin 5-HT2 Receptor Antagonists Phase 4
19 Serotonin 5-HT1 Receptor Agonists Phase 4
20 Dopamine Antagonists Phase 4
21 Serotonin Agents Phase 4
22 Antipsychotic Agents Phase 4
23 Antidepressive Agents Phase 4
24 Dopamine agonists Phase 4
25 Serotonin Receptor Agonists Phase 4
26 Serotonin Antagonists Phase 4
27 Hypolipidemic Agents Phase 4
28 Rosuvastatin Calcium Phase 4 147098-20-2
29 Anticholesteremic Agents Phase 4
30 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
31 Antimetabolites Phase 4
32 Lipid Regulating Agents Phase 4
33 Mace Phase 4
34 Follicle Stimulating Hormone Phase 4
35 Pharmaceutical Solutions Phase 4
36 Phosphodiesterase 5 Inhibitors Phase 4
37 Phosphodiesterase Inhibitors Phase 4
38 Vardenafil Dihydrochloride Phase 4
39 Vasodilator Agents Phase 4
40
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
41
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
42
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
43
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
44
Amphetamine Approved, Illicit, Investigational Phase 3 300-62-9 5826 3007
45
Histamine Approved, Investigational Phase 3 51-45-6 774
46
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
47
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
48
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
49
tannic acid Approved Phase 3 1401-55-4
50
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 395)
# Name Status NCT ID Phase Drugs
1 Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin is Superior to Human Chorionic Gonadotropin in Therapeutic Efficacy in Adolescent Boys With Congenital Hypogonadotropic Hypogonadism Unknown status NCT02880280 Phase 4 Human Menopausal Gonadotropin;Human Chorionic Gonadotropin
2 The Effect of Testim and Training in a Population Based, Randomized, Placebo-controlled, Double-blinded Study of Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
3 Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
4 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
5 Study on the Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
6 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation by Using Recombinant Luteinizing Hormone (rLH) and Recombinant Follicle Stimulating Hormone (rFSH) in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
7 Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism Completed NCT01107067 Phase 4 Sustanon
8 Phase 4 Study of About the Effect of Testosterone Treatment on the Components of Metabolic Syndrome Completed NCT01160341 Phase 4 Testosteron
9 Effects of Three Different Medications on Metabolic Parameters and Testicular Volume in Patients With Hypogonadotropic Hypogonadism-Last Three Years Experience Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
10 Effects of Liraglutide and Testosterone Replacement Therapy on Features of Hypogonadism and Weight Loss in Obese Men With Persistent Features of Hypogonadism. Completed NCT03619330 Phase 4 liraglutide;Testosterone
11 Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111434 Phase 4 Testosterone
12 Phase 4 Study That Evaluates the Presence of Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism and Effects of Two Different Testosterone Replacement Regiments on These Parameters. Completed NCT02171390 Phase 4 Testosterone 250mg injection;Testosteron 50 mg transdermal gel
13 Phase 4 Study That Evaluates the Effects of Two Different Testosterone Replacement Regiments on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism. Completed NCT01533129 Phase 4 Testogel 50 mg transdermal gel;Testosterone 250mg injection
14 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed NCT01893281 Phase 4 Topical Testosterone Solution
15 Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups. Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
16 Efficacy and Safety of Human Chorionic Gonadotropin (HCG) and Follicle Stimulating Hormone (FSH) in the Treatment of Hypogonadotropic Hypogonadism Completed NCT01403532 Phase 4 Traditional intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH plus zinc
17 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
18 A Randomised, Double Blind, Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus Completed NCT00504712 Phase 4 Testosterone;saline
19 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
20 Phase 4 Study of Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
21 A Randomised, Double Blind, Placebo-controlled Parallel Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus Completed NCT00355537 Phase 4 Testosterone;0.9% saline
22 Testosterone Replacement and Dutasteride Effectiveness (TRADE) Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
23 Effect of Testosterone Replacement on Insulin Resistance in Hypogonadal, Non-obese Men With Metabolic Syndrome Completed NCT00487734 Phase 4 Placebo for testosterone gel
24 Phase IV Study of The Therapy of Long-acting Testosterone Undecanoate,1000mg in 4 ml Oily Solution for i.m.Injection(Nebido) as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
25 A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Androgen Levels in Hypogonadal Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
26 Testosterone Replacement in Metabolic Syndrome and Inflammation of Fat Tissue Completed NCT01123278 Phase 4 Testosterone;Placebo
27 A Randomised Double Blind Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Replacement on Glycaemic Control and Arterial Wall Properties of Hypogonadal Men With Type 2 Diabetes Treated With Insulin Completed NCT00349362 Phase 4 Testosterone;0.9% saline
28 Effect of Hypogonadotrophic Hypogonadism and Treatment With Testosterone on Insulin Sensitivity, Inflammation, Body Composition and Sexual Function in Obese and Type 2 Diabetic Men Completed NCT01127659 Phase 4 testosterone;placebo
29 Aripiprazole Treatment for Antipsychotic Induced Hyperprolactinaemia in Patients With Severe Mental Illness and Learning Disabilities Completed NCT01085383 Phase 4 Aripiprazole
30 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) - a Randomised, Doubleblinded and Placebocontrolled Trial of Men With Subnormal Testosterone Levels and T2DM. Completed NCT01560546 Phase 4 Testosterone;Placebo
31 A 150-Day, Prospective, Phase 4, Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Testosterone Nasal Gel (Natesto™) Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
32 Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: "Implications for Prostate Safety" Completed NCT00752869 Phase 4 dutasteride;placebo
33 Effects of Testosterone on Myocardial Repolarization in Patients With Hypogonadism With/Without Chronic Heat Failure (NYHA Class I-II) Completed NCT03126656 Phase 4 Testosterone Undecanoate
34 Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
35 Statin Therapy is Associated With Low Testosterone and Sexual Function in Men With Type 2 Diabetes Completed NCT02612714 Phase 4 Rosuvastatin
36 To Define the Individual Need of Exogenous LH During Ovarian Stimulation for Severe LH Suppressed Patients After Administration of a GnRH Antagonist Completed NCT01936077 Phase 4 Recombinant LH (Luveris)
37 Subcutaneous Testosterone Therapy in Men Compared to Intramuscular Testosterone Therapy in Men Completed NCT03091348 Phase 4 Testosterone
38 Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
39 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Completed NCT01201863 Phase 4 Androgel (Testosterone Gel);Androgel Placebo
40 Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
41 Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG Completed NCT01638026 Phase 4 TRIPTORELIN ACETATE, hCG
42 Combined Influence of Puberty and Obesity on Insulin Resistance in Adolescents Completed NCT01775813 Phase 4 Metformin
43 Effects of Testosterone Replacement on Atherosclerosis Progression in Older Men With Low Testosterone Levels Completed NCT00287586 Phase 4 Testosterone Gel (Androgel);Placebo
44 FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women Completed NCT02674178 Phase 4
45 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
46 Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study Recruiting NCT03518034 Phase 4 Testosterone;Placebo
47 The Effect of Testosterone Replacement in Patients With Hypogonadotrophic Hypogonadism Due to Opioid Treatment for Non-malignant Disease Recruiting NCT02433730 Phase 4 Testosterone;placebo
48 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Recruiting NCT03203681 Phase 4 NATESTO® (4.5% nasal testosterone) Nasal Gel
49 Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism Recruiting NCT03490513 Phase 4 anastrozole (1 mg/day);Placebo
50 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism Recruiting NCT03887936 Phase 4 Testosterone gel 1.62%;Placebo

Search NIH Clinical Center for Hypogonadism

Inferred drug relations via UMLS 71 / NDF-RT 50 :


2-Bromoergocryptine Mesylate
Black Cohosh Extract
Bromocriptine
Chlorotrianisene
Estradiol
Estradiol acetate
estradiol cypionate
ESTRADIOL PWDR
estradiol valerate
Estrogens
Estrogens, Conjugated (USP)
Estrogens, Esterified (USP)
Estrone
estropipate
Ethinyl Estradiol
Ethynodiol Diacetate
Fluoxymesterone
Methyltestosterone
METHYLTESTOSTERONE PWDR
Norethindrone
norethindrone acetate
polyestradiol
polyestradiol phosphate
Sodium estrone sulfate
synthetic conjugated estrogens, A
synthetic conjugated estrogens, B
Testosterone
testosterone cypionate
testosterone enanthate
Testosterone Propionate
TESTOSTERONE PROPIONATE PWDR
TESTOSTERONE PWDR
testosterone undecanoate

Cochrane evidence based reviews: hypogonadism

Sources

Genetic Tests for Hypogonadism

About this section

Genetic tests related to Hypogonadism:

# Genetic test Affiliating Genes
1 Hypogonadism 29
Sources

Anatomical Context for Hypogonadism

About this section

MalaCards organs/tissues related to Hypogonadism:

40
Pituitary, Bone, Prostate, Testes, Liver, Brain, Thyroid
Sources

Publications for Hypogonadism

About this section

Articles related to Hypogonadism:

(show top 50) (show all 10214)
# Title Authors PMID Year
1
Novel insights in FGFR1 regulation: lessons from Kallmann syndrome. 54 61
20117945 2010
2
Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality. 54 61
19656574 2010
3
[Case of progressive prostatic carcinoma in a patient with acquired hypogonadism]. 54 61
20448451 2010
4
A new FSHbeta mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. 54 61
19966036 2010
5
Management of erectile dysfunction. 54 61
20112889 2010
6
Recombinant follitropin alfa/lutropin alfa in fertility treatment. 54 61
20161981 2010
7
The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction. 54 61
19912506 2010
8
Narrative review: the role of leptin in human physiology: emerging clinical applications. 54 61
20083828 2010
9
Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. 54 61
19226407 2009
10
Relationship between insulin and hypogonadism in men with metabolic syndrome. 54 61
20126854 2009
11
Prostate cancer and acromegaly. 54 61
20126848 2009
12
Adiponectin and testosterone in patients with symptoms of late-onset hypogonadism: is there a link? 54 61
19719531 2009
13
Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. 54 61
19523548 2009
14
Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism. 54 61
19458139 2009
15
Dimeric PROP1 binding to diverse palindromic TAAT sequences promotes its transcriptional activity. 54 61
19524124 2009
16
The emerging link between hypogonadism and metabolic syndrome. 54 61
18772486 2009
17
Bone mineral density and disorders of mineral metabolism in chronic liver disease. 54 61
19630107 2009
18
Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls. 54 61
19344792 2009
19
Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. 54 61
19154450 2009
20
Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. 54 61
19176467 2009
21
Leptin: a pivotal regulator of human energy homeostasis. 54 61
19211814 2009
22
Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. 54 61
19156143 2009
23
Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. 54 61
19347183 2009
24
Has prolactin a role in the hypogonadal status of HIV-infected patients? 54 61
19171915 2009
25
Inactivating mutations of luteinizing hormone beta-subunit or luteinizing hormone receptor cause oligo-amenorrhea and infertility in women. 54 61
19129711 2009
26
FSHbeta gene mutation in a female with delayed puberty and hypogonadism: response to recombinant human FSH. 54 61
20067895 2009
27
Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. 54 61
18854428 2008
28
Laboratory diagnosis of late-onset male hypogonadism andropause. 54 61
19197450 2008
29
Relationship of prostate-specific antigen to age and testosterone in men with type 2 diabetes mellitus. 54 61
19095599 2008
30
[Long-term steroid therapy in children: is adjunct therapy relevant in nephrotic syndrome?]. 54 61
18951767 2008
31
Left ventricular dysfunction in Klinefelter syndrome is associated to insulin resistance, abdominal adiposity and hypogonadism. 54 61
18248650 2008
32
Testosterone and erectile dysfunction. 54 61
18641415 2008
33
Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). 54 61
18429947 2008
34
Acylated ghrelin and leptin in adolescent athletes with amenorrhea, eumenorrheic athletes and controls: a cross-sectional study. 54 61
18331605 2008
35
[Testosterone replacement in hypogonadotropic hypogonadal young male improves insulin sensitivity]. 54 61
19080648 2008
36
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. 54 61
18449947 2008
37
Kisspeptin and GPR54: discovery of a novel pathway in reproduction. 54 61
18601695 2008
38
Bone density in the adolescent athlete. 54 61
18409004 2008
39
The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. 54 61
18343420 2008
40
Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. 54 61
18195686 2008
41
Prevalence of androgen deficiency in men with erectile dysfunction. 54 61
18313109 2008
42
[Phenotype of patients with gynecomastia]. 54 61
18465688 2008
43
The role of cyclase activating (CAP) and cyclase inhibiting (CIP) parathormone fractions in the assessment of bone metabolism disturbances in women with hyperprolactinemia of various origin. 54 61
18283239 2008
44
Seminiferous tubule function in delayed-onset X-linked adrenal hypoplasia congenita associated with incomplete hypogonadotrophic hypogonadism. 54 61
17803711 2008
45
Secondary hypothyroidism in hereditary hemochromatosis: recovery after iron depletion. 54 61
18205549 2008
46
Cholestasis and metabolic bone disease - a clinical review. 54 61
18998071 2008
47
Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. 54 61
19554077 2008
48
Metabolic syndrome and reproduction: I. testicular function. 54 61
18224542 2008
49
The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al. 54 61
18987492 2008
50
Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? 54 61
18447401 2008
Sources

Variations for Hypogonadism

About this section
Sources

Expression for Hypogonadism

About this section
Search GEO for disease gene expression data for Hypogonadism.
Sources

Pathways for Hypogonadism

About this section

Pathways related to Hypogonadism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 13.73 TACR3 TAC3 PROKR2 PROK2 LHCGR LHB
2
Peptide ligand-binding receptors 65
Show member pathways
 12.98 TACR3 TAC3 PROKR2 PROK2 LHCGR LHB
3
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.29 LHB GNRHR GNRH1 FSHB
4
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 11.94 LHB GNRH1 FGFR1 FGF17
5
G alpha (s) signalling events 65
11.8 LHCGR LHB FSHB
6
G-protein signaling_RhoA regulation pathway 22
11.36 LHB GNRH1 FGFR1 FGF17
7
GnRH secretion 36
11.36 LHB KISS1R KISS1 GNRH1
8
Ovarian steroidogenesis 36
11.19 LHCGR LHB FSHB
9
Hormone ligand-binding receptors 65
10.14 LHCGR LHB GNRHR GNRH1 FSHB
Sources

GO Terms for Hypogonadism

About this section

Cellular components related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 TAC3 PROK2 LHB KISS1 GNRH1 FSHB

Biological processes related to Hypogonadism according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.1 TACR3 PROKR2 LHCGR LHB KISS1R GNRHR
2 male gonad development GO:0008584 9.65 NR0B1 LHCGR LHB
3 female pregnancy GO:0007565 9.63 TAC3 GNRH1 FSHB
4 fibroblast growth factor receptor signaling pathway GO:0008543 9.58 FGFR1 FGF17 ANOS1
5 peptide hormone processing GO:0016486 9.51 LHB FSHB
6 male sex determination GO:0030238 9.43 NR0B1 GNRH1
7 hormone-mediated signaling pathway GO:0009755 9.43 LHCGR LHB FSHB
8 cellular response to gonadotropin stimulus GO:0071371 9.37 NSMF LHCGR
9 G protein-coupled receptor signaling pathway GO:0007186 9.36 TACR3 TAC3 PROKR2 PROK2 LHCGR LHB
10 tachykinin receptor signaling pathway GO:0007217 9.32 TACR3 TAC3
11 neuropeptide signaling pathway GO:0007218 9.26 TAC3 PROKR2 PROK2 KISS1R
12 progesterone biosynthetic process GO:0006701 9.16 LHB FSHB

Molecular functions related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 LHB GNRH1 FSHB
2 protein-hormone receptor activity GO:0016500 8.62 LHCGR GNRHR
Sources

Sources for Hypogonadism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....